Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study
Clinical and Experimental Dermatology · 21.05.2024 · 49 (6) · 578-583
DOI: 10.1093/ced/llae013 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 08.01.2024. Verfasst von Mozhgan Hosseini-Ashrafi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Severity of Illness Index. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Dupilumab is licensed for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 6 months.
Objectives
The aim of this study was to examine real-world outcomes and safety of dupilumab in British children with moderate-to-severe AD attending a tertiary referral paediatric centre.
Methods
Skin and quality of life scores, adverse events and discontinuation rates were assessed. Patients aged ≤ 18 years with moderate-to-severe AD were included if they had skin scores recorded at baseline and at least one follow-up visit. Efficacy and safety were assessed using descriptive statistics.
Results
In this retrospective observational survey, 72 children/teenagers, with a median age of 14 years (range 7–18) were included. Oral systemic immunosuppressants had failed to control AD in 88% of children recruited. All patients commenced on dupilumab had pretreatment eczema skin scores consistent with moderate-to-severe disease, with a median Eczema Area and Severity Index (EASI) score of 25 [interquartile range (IQR) 20–31]. EASI scores decreased by a median of 94% (IQR 82–100) and remained consistently low over 10–52 months of the study, with a median EASI score at final follow-up of 2 (IQR 0–6). Of the 72 children, 8 (11%) were able to discontinue dupilumab as they were in remission. Nineteen (26%) experienced adverse events, most commonly conjunctivitis (12 patients; 17%). Eight (11%) discontinued dupilumab (six with ongoing inflammatory skin flares, one with severe allergic conjunctivitis, one with intercurrent Wilson disease).
Conclusions
Dupilumab was highly effective in treating most children with moderate-to-severe AD with good safety outcomes in the real world. However, 10% of children may need alternative therapy because of drug ineffectiveness or side-effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
- Department of Paediatric Dermatology, Royal Manchester Children's Hospital, Manchester, UK.
- Department of Paediatric Allergy & Immunology, Royal Manchester Children's Hospital, Manchester, UK.
- The Lydia Becker Institute of Immunology and Inflammation, The University of Manchester, Manchester, UK.
Zitieren
APA
Hosseini-Ashrafi, M., Clayton, T. H., Herring, M., Herety, N., & Arkwright, P. D. (2024). Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study. Clinical and Experimental Dermatology, 49(6), 578-583. https://doi.org/10.1093/ced/llae013
Vancouver
Hosseini-Ashrafi M, Clayton TH, Herring M, Herety N, Arkwright PD. Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study. Clinical and Experimental Dermatology. 2024;49(6):578-583. doi:10.1093/ced/llae013
BibTeX
@article{HosseiniAshrafi2024,
author = {Hosseini-Ashrafi, Mozhgan and Clayton, Tim H and Herring, Michelle and Herety, Nichola and Arkwright, Peter D},
title = {Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study},
journal = {Clinical and Experimental Dermatology},
year = {2024},
volume = {49},
number = {6},
pages = {578--583},
doi = {10.1093/ced/llae013}
}
EUVIMED